Business Context and Reporting Period
This Form 6-K filing by GSK plc (the "Company") reports a transaction in its own shares for the month of March 2025. The filing details a share repurchase executed on March 14, 2025, pursuant to a non-discretionary agreement with Citigroup Global Markets Limited entered into on February 24, 2025.
Key Financial Metrics
- Shares Purchased: 690,000 ordinary shares of 31½ pence each.
- Price Range: Lowest price paid was 1,495.50p; highest price paid was 1,513.50p.
- Average Price: Volume-weighted average price paid was 1,505.01p.
- Treasury Shares: Following this purchase, the Company holds 179,531,345 ordinary shares in treasury.
- Shares in Issue: 4,135,673,947 ordinary shares (excluding Treasury shares).
- Voting Rights: Total voting rights are 4,135,673,947.
- Cumulative Buyback: Since February 24, 2025, the Company has purchased 10,461,042 ordinary shares.
Material Changes
The filing does not report changes in revenue, profit, or operating margins. The primary material change is the reduction in outstanding shares and the increase in treasury shares resulting from the buyback program. The filing text does not provide a clear value for the total cash outflow for this specific transaction, though it can be estimated based on the volume-weighted average price.
Guidance, Outlook, and Risks
The filing contains no new financial guidance or management commentary regarding future operational performance. It includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially due to risks described in the GSK 2024 Annual Report on Form 20-F (pages 277 to 285). The purchased shares are held as Treasury shares.
Investor Verification Checklist
- Verify the total remaining authorization under the existing buyback program.
- Confirm the impact of the increased treasury share count on earnings per share (EPS) calculations.
- Review the GSK 2024 Annual Report on Form 20-F for the specific risk factors referenced in the cautionary statement.
- Monitor subsequent filings for further repurchase activity under the non-discretionary agreement.